NCT00063388View on ClinicalTrials.gov

Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Non-Small-Cell Lung Cancer
Interventions
BIOLOGICAL

Cetuximab

Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).

Trial Locations (8)

33140

ImClone Investigational Site, Miami Beach

33180

ImClone Investigational Site, Aventura

46202

ImClone Investigational Site, Indianapolis

46601

ImClone Investigational Site, South Bend

60612

ImClone Investigational Site, Chicago

63110

ImClone Investigational Site, St Louis

02114

ImClone Investigational Site, Boston

02115

ImClone Investigational Site, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY